Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:barrelLength |
high
|
| gptkbp:clinicalTrials |
Phase 1
|
| gptkbp:collaborations |
clinical research organizations
|
| gptkbp:contraindication |
to be determined
|
| gptkbp:currentStatus |
completed
|
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:dosageForm |
every 2 weeks
|
| gptkbp:firstClaim |
combination therapy
|
| gptkbp:firstMatch |
2020
|
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb18092
|
| gptkbp:mandates |
cancer
|
| gptkbp:marketSegment |
not approved
|
| gptkbp:patentStatus |
patented
|
| gptkbp:relatedTo |
immune system
|
| gptkbp:researchFocus |
oncology
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
under evaluation
|
| gptkbp:status |
investigational
|
| gptkbp:targets |
PD-1
|
| gptkbp:triggerType |
immune checkpoint inhibition
|
| gptkbp:type |
IgG1
|